Neeraj Agarwal, MD, FASCO(@neerajaiims) 's Twitter Profileg
Neeraj Agarwal, MD, FASCO

@neerajaiims

Medical Oncologist. Editor-in-chief: @ASCO Daily News; Presidential Endowed Chair, @HuntsmanCancer (NCI-CCC) @UUtah, FCOI https://t.co/ywWAdZmBWt

ID:4761682514

linkhttps://bit.ly/3JApRJd calendar_today15-01-2016 06:32:10

12,5K Tweets

14,3K Followers

786 Following

UroToday.com(@urotoday) 's Twitter Profile Photo

Exciting news in treatment! Alicia Morgans, MD, MPH interviews Neeraj Agarwal, MD, FASCO about the groundbreaking -02 trial, showcasing the promising combination of cabozantinib and atezolizumab in patients. on UroToday > bit.ly/3OZiLTG Bayer | Pharmaceuticals

Exciting news in #ProstateCancer treatment! @CaPsurvivorship interviews @neerajaiims about the groundbreaking #CONTACT-02 trial, showcasing the promising combination of cabozantinib and atezolizumab in #mCRPC patients. #WatchNow on UroToday > bit.ly/3OZiLTG @BayerPharma
account_circle
Advanced Prostate Cancer Consensus Conference(@APCCC_Lugano) 's Twitter Profile Photo

With less than a week until begins, we’re highlighting again the crucial sessions on systemic therapy side effects and metastatic CRPC management.

Whether you join us in the city of Lugano🇨🇭or tune in virtually, these discussions are pivotal for anyone interested in

account_circle
SWOG Cancer Research Network(@SWOG) 's Twitter Profile Photo

Our C Blanke, SWOG Chair blog:
More Results: SWOG Trials That Keep on Giving
To keep @SWOG members informed of our research results, I'm highlighting important findings presented at two recent meetings, in cancer and rare carcinoma lung tumors
swog.org/news-events/ne…

Our @SWOGChair blog: More Results: SWOG Trials That Keep on Giving To keep @SWOG members informed of our research results, I'm highlighting important findings presented at two recent meetings, in #prostate cancer and rare #sarcomatoid carcinoma lung tumors swog.org/news-events/ne…
account_circle
IMG Oncologists(@IMG_Oncologists) 's Twitter Profile Photo

🚨Save the date 🚨
ASCO International Medical Graduates Community of Practice Meeting
⏰May 31st, 4-6 PM CST
📌Room S103, McCormick Place
Join us to discuss barriers & opportunities for IMGs in
ASCO IMG CoP 👉bit.ly/3JmJQwK
ASCOPost

🚨Save the date 🚨 @ASCO International Medical Graduates Community of Practice Meeting ⏰May 31st, 4-6 PM CST 📌Room S103, McCormick Place Join us to discuss barriers & opportunities for IMGs in #oncology ASCO IMG CoP 👉bit.ly/3JmJQwK @ASCOPost #IMG #MedEd #MedTwitter
account_circle
Vamsi Velcheti, MD MBA(@VamsiVelcheti) 's Twitter Profile Photo

💡 Innovation in cancer treatment starts with robust funding. Demand congress to support $51.303B for NIH and $7.934B for NCI to keep pace with biomedical inflation& foster growth; staggering amount of vital cancer research remains unfunded due to insufficient resources. Support

💡 Innovation in cancer treatment starts with robust funding. Demand congress to support $51.303B for NIH and $7.934B for NCI to keep pace with biomedical inflation& foster growth; staggering amount of vital cancer research remains unfunded due to insufficient resources. Support
account_circle
Oncology Brothers(@OncBrothers) 's Twitter Profile Photo

KN564: Pembro was approved for high risk adj RCC in Nov 2021 based off this study. Now on NEJM w/ OS benefit.

- DFS HR: 0.72 and OS HR: 0.62
- At 48 mos, OS 91.2% w/ vs 86%
- Toni Choueiri, MD Tian Zhang, MD, MHS Tom Powles et al. 👏👏👏

KN564: Pembro was approved for high risk adj RCC in Nov 2021 based off this study. Now on @NEJM w/ OS benefit. - DFS HR: 0.72 and OS HR: 0.62 - At 48 mos, OS 91.2% w/ #Pembrolizumab vs 86% - @DrChoueiri @TiansterZhang @tompowles1 et al. 👏👏👏 #OncTwitter #MedTwitter #GUSM
account_circle
Toni Choueiri, MD(@DrChoueiri) 's Twitter Profile Photo

1/ The long-awaited OS results from -564 are out NEJM! The 1st phase 3 trial to demonstrate a survival benefit for adjuvant treatment in .

nejm.org/doi/full/10.10…

1/ The long-awaited OS results from #KEYNOTE-564 are out @NEJM! The 1st phase 3 trial to demonstrate a survival benefit for adjuvant treatment in #RCC. nejm.org/doi/full/10.10…
account_circle
Sonam Puri MD(@Sonampuri) 's Twitter Profile Photo

'Grateful to ASCO for the incredible opportunity to participate in the
Connecting with legislators and advocating for crucial issues like funding was truly inspiring!

Together, we're making a difference!

'Grateful to @ASCO for the incredible opportunity to participate in the #ASCOAdvocacySummit Connecting with legislators and advocating for crucial issues like #DrugShortages #telehealth #CancerResearch funding was truly inspiring! Together, we're making a difference!
account_circle
OncoAlert(@OncoAlert) 's Twitter Profile Photo

The OncoAlert 🚨 Network is Proud to be collaborating with our friends at Advanced Prostate Cancer Consensus Conference

NEXT WEEK: April 25-27, 2024
Register Here onlineevent.ch/APCCC/2024
ONLINE REGISTRATION FREE FOR SOME LMIC's

Follow Our Ambassadors for coverage of this Great event in

account_circle
Neli Ulrich, PhD(@NeliMUlrich) 's Twitter Profile Photo

Thank you so much to all our Lab Professionals! You make sure that essential results get quickly & accurately back to the clinic and labs. Appreciate your diligent work! 🧪👩‍🔬 Neeraj Agarwal, MD, FASCO Tom Varghese Jr. MD, MS, MBA, FACS, MAMSE 🇺🇸

account_circle
Guru P. Sonpavde, MD(@sonpavde) 's Twitter Profile Photo

AACR⁩ - Selected Highlights of data (in my opinion)- focus on early clinical drug development of single agent therapy for VuMedi⁩ ⁦Vivek Subbiah, MD⁩ ⁦Sumanta K. Pal, MD, FASCO⁩ ⁦Neeraj Agarwal, MD, FASCO⁩ vumedi.com/video/clinical…

account_circle
OncoAlert(@OncoAlert) 's Twitter Profile Photo

The OncoAlert🚨NEWSLETTER OUT‼️
Covering April 12-18, 2024

REGISTER at OncoAlert360.com OR oncoalert.m-pages.com/nhMpwe/oncoale…

COVERING
✅NEW Prostate guidelines European Association of Urology (EAU)
✅The Lancet Commission
✅1st line Pembro & cemiplimab in🫁 🧪
✅RADICALS RT ☢️in

account_circle